Skip to main content
. 2023 Oct 7;13:16950. doi: 10.1038/s41598-023-44039-0

Figure 6.

Figure 6

Selinexor (Sel) in combination with acalisib (Aca) is effective in reducing the tumor burden in vivo. Mice transplanted with the Eµ-TCL1-derived leukemia were randomly treated with selinexor and acalisib, used as single agents or in combination, or with a vehicle. A schematic outline of in vivo experiments is depicted in (a). (b) Shows the percentage of leukemic cells (CD5+/B220+ cells) in the spleen of mice transplanted with the Eµ-TCL1-derived leukemia after 2 weeks of treatment. (c) shows the macroscopic view of the spleens from two representative animals for each treatment group, and (d) shows the spleen volume for all treated animals. In (b) and (d) box and whiskers plots represent median values, 25–75% percentiles, and minimum and maximum values for each group; each point represents a single sample. **p < 0.01 and *p < 0.05.